Liquidia Corp (LQDA)
12.96
-0.21
(-1.59%)
USD |
NASDAQ |
May 02, 14:13
Liquidia Cash from Investing (Quarterly): -0.206M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.206M |
| September 30, 2023 | -10.48M |
| June 30, 2023 | -0.243M |
| March 31, 2023 | -0.364M |
| December 31, 2022 | -0.491M |
| September 30, 2022 | -0.094M |
| June 30, 2022 | -0.002M |
| March 31, 2022 | 0.00 |
| December 31, 2021 | -0.02M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | -0.035M |
| March 31, 2021 | -0.052M |
| December 31, 2020 | 0.961M |
| September 30, 2020 | -0.1225M |
| Date | Value |
|---|---|
| June 30, 2020 | -0.4084M |
| March 31, 2020 | -0.1822M |
| December 31, 2019 | -0.1339M |
| September 30, 2019 | -0.636M |
| June 30, 2019 | -0.8349M |
| March 31, 2019 | -0.2453M |
| December 31, 2018 | -0.1011M |
| September 30, 2018 | -0.1399M |
| June 30, 2018 | -0.3729M |
| March 31, 2018 | -0.2571M |
| December 31, 2017 | -1.294M |
| September 30, 2017 | -1.039M |
| June 30, 2017 | -0.1602M |
| March 31, 2017 | -0.0508M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-10.48M
Minimum
Sep 2023
0.961M
Maximum
Dec 2020
-0.702M
Average
-0.1339M
Median
Dec 2019
Cash from Investing (Quarterly) Benchmarks
| United Therapeutics Corp | 42.10M |
| AIM ImmunoTech Inc | -0.214M |
| Perspective Therapeutics Inc | -0.089M |
| Protalix BioTherapeutics Inc | -0.342M |
| Armata Pharmaceuticals Inc | -2.39M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -15.98M |
| Cash from Financing (Quarterly) | 23.64M |
| Free Cash Flow | -52.85M |
| Free Cash Flow Per Share (Quarterly) | -0.2465 |
| Free Cash Flow to Equity (Quarterly) | -16.19M |
| Free Cash Flow Yield | -6.27% |